Researchers at the HUN-REN Biological Research Centre, Szeged, Hungary, have developed an artificial-intelligence-assisted technology capable of analyzing up to one hundred patient-derived cell samples simultaneously.

The new method, described in Nature Communications, could significantly accelerate drug development and advance the field of personalized medicine.

Researchers at the HUN-REN Biological Research Centre in Szeged, Hungary, have developed an artificial-intelligence-assisted technology capable of analyzing up to one hundred patient-derived cell samples simultaneously.

The new method, described in Nature Communications, could significantly accelerate drug development and advance the field of personalized medicine.

Dr. LU Ming's group from the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences, in collaboration with researchers from Huashan Hospital of Fudan University, has now identified a key acetate source by revealing how HCC cells trigger acetate secretion by tumor-associated macrophages (TAMs) through a metabolic interaction involving lactate and the lipid peroxidation–aldehyde dehydrogenase 2 (ALDH2) pathway.

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary human T cells, addressing a key manufacturing and scalability challenge in next-generation cell therapies. The research, published October 21, 2025, in Nature Biotechnology, demonstrates how CRISPRoff and CRISPRon can reprogram a patient’s own T cells for therapeutic purposes without the cell toxicity and DNA damage associated with traditional gene editing approaches.

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented this week at the European Society for Medical Oncology (ESMO) Congress 2025.

The Jackson Laboratory (JAX), a global leader in genetics and genomic medicine, has completed its acquisition of the New York Stem Cell Foundation (NYSCF), a pioneering nonprofit dedicated to advancing cures through stem cell research.

Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat form of leukemia. The results of Alliance A041703 Cohort 1, published in the Journal of Clinical Oncology, focused on treating patients aged 60 years and older with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) with immunotherapy medications inotuzumab ozogamicin and blinatumomab. Historically, this group has faced poor outcomes with traditional chemotherapy due to high rates of treatment-related death and relapse.